Article Data

  • Views 476
  • Dowloads 170

Review

Open Access

The interaction of drugs to treat cardiovascular diseases and testosterone therapy, their effects and characteristics

  • Duygun Altıntaş Aykan1
  • Ahmet Çağrı Aykan2

1Department of Pharmacology, Kahramanmaras Sütçü Imam University, Faculty of Medicine, 55120 Kahramanmaras, Turkey

2Department of Cardiology, Kahramanmaras Sütçü Imam University, Faculty of Medicine, 55120 Kahramanmaras, Turkey

DOI: 10.31083/jomh.2021.005 Vol.17,Issue 2,April 2021 pp.25-31

Published: 08 April 2021

*Corresponding Author(s): Duygun Altıntaş Aykan E-mail: altintasduygun_dr@yahoo.com

PDF (109.66 kB)

Abstract

Testosterone is used in the treatment of primary or acquired hypogonadism, constitutional growth retardation, and delayed puberty in male patients. Today, there is a fact that cardiovascular diseases present a high frequency in males with a marked tendency to increase soon. Therefore, the number of men using drugs to treat cardiovascular diseases is increasing rapidly. Cardiovascular drugs, which are frequently used and/or recently introduced, may cause undesirable effects under the heading of drug-drug interaction with testosterone therapy. The number of male patients exposed to these agents may increase rapidly quite soon. In this paper, we reviewed the potential drug-drug interactions between drugs to treat cardiovascular diseases and testosterone treatment considering the pharmacokinetic parameters and experimental animal studies in the literature.

Keywords

Testosterone; Drug interactions; Drug-induced; Cardiovascular drugs

Cite and Share

Duygun Altıntaş Aykan,Ahmet Çağrı Aykan. The interaction of drugs to treat cardiovascular diseases and testosterone therapy, their effects and characteristics. Journal of Men's Health. 2021. 17(2);25-31.

References

[1] Yeap BB, Wu FCW. Clinical practice update on testosterone therapy for male hypogonadism: Contrasting perspectives to optimize care. Clinical Endocrinology. 2019; 90: 56-65.

[2] Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, Almeida OP, et al. In older men, higher plasma testosterone or dihydrotestosterone are independent predictors for reduced incidence of stroke but not myocardial infarction. The Journal of Clinical Endocrinology & Metabolism. 2014; 99: 4565-4573.

[3] Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, Almeida OP, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. The Journal of Clinical Endocrinology & Metabolism. 2014; 99: E9-18.

[4] Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. the New England Journal of Medicine. 2010; 363: 109-122.

[5] Ambrisentan-drug information. Available at: https://www. uptodate.com/contents/ambrisentan-druginformation (Accessed: 1 October 2020).

[6] Hansten PD, Horn JR. Cytochrome P450 enzymes and drug interac-tions, table of cytochrome P450 substrates, inhibitors, inducers and p-glycoprotein, with footnotes. In: the top 100 drug interactions-a guide to patient management. Freeland, WA: H&H Publications. 2008; 142-157.

[7] Review Editor B. Letairis (ambrisentan) PharmaDeals Review. 2007.

[8] AMBRİSENTAN. Available at: https://www. micromedexsolutions.com/reprotox (Accessed: 1 September 2020).

[9] Carvedilol-drug-information. Available at: https://www. uptodate.com/contents/carvedilol-drug-information (Accessed: 5 October 2020).

[10] Barnes KM, Dickstein B, Cutler GB Jr, Fojo T, Bates SE. Steroid treat-ment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry. 1996; 35: 4820-4827.

[11] Food and Drug Administration (FDA). Drug development and drug interactions. 2012. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInte (Accessed: 13 October 2020).

[12] Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Character-ization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundamental & Clinical Pharmacology. 2006; 20: 273-282.

[13] GlaxoSmithKline. Coreg product label. 2017. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo. cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68(Accessed: 13 October 2020).

[14] Morsy M, Ramzy M, El-Sheikh AK, Kamel M, Abdelwahab S. Mechanism of testicular protection of carvedilol in streptozotocin-induced diabetic rats. Indian Journal of Pharmacology. 2014; 46: 161.

[15] Conivaptan-drug-information. Available at: https://www. uptodate.com/contents/conivaptan-drug-information (Accessed: 8 October 2020).

[16] Vaprisol (conivaptan hydrochloride injection) package insert. Deer-field, IL: Baxter Healthcare Corporation. 2016.

[17] Krauser JA, Guengerich FP. Cytochrome P450 3A4-catalyzed testos-terone 6beta-hydroxylation stereochemistry, kinetic deuterium iso-tope effects, and rate-limiting steps. Journal of Biological Chemistry. 2005; 280: 19496-19506.

[18] Drug Development and Drug Interactions. Table of Substrates, Inhibitors and Inducers. 2020. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm (Accessed: 8 October 2020).

[19] Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation. Alphen aan den Rijn, The Netherlands. 2017.

[20] Boehringer Ingelheim Pharmaceuticals. Product information: Pradaxa. Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals. 2018.

[21] Dabigatran-drug-information. Available at: https://www. uptodate.com/contents/dabigatran-drug-information (Accessed: 7 September 2020).

[22] Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2020.

[23] Dronedarone-drug-information. Available at: https://www. uptodate.com/contents/dronedarone-drug-information (Accessed: 7 September 2020).

[24] Multaq (dronedarone) package insert. Bridgewater, NJ: Sanofi-aventis. 2014.

[25] Daiichi Sankyo. Product information: Savaysa. Tokyo, Japan, Daiichi Sankyo. 2015.

[26] Edoxaban-drug-information. Available at: https://www. uptodate.com/contents/edoxaban-drug-information (Accessed: 6 October 2020).

[27] Savaysa (edoxaban) package insert. Basking Ridge, NJ: Daiichi Sankyo, Inc. 2020.

[28] Edoxaban. Available at: https://www.micromedexsolutions. com/reprotox (Accessed: 1 October 2020).

[29] Propranolol-drug-information. Available at: https://www. uptodate.com/contents/propranolol-drug-information (Accessed: 1 October 2020).

[30] Androgel 1% (testosterone gel) package insert. North Chicago, IL: Abbott Laboratories. 2019.

[31] Ranolazine-drug-information. Available at: https://www.uptodate.com/contents/ranolazine-drug-information (Accessed: 20 September 2020).

[32] Ranexa (ranolazine extended-release tablets) package insert. Foster City, CA: Gilead Sciences, Inc. 2019.

[33] Janssen Pharmaceuticals Product information: Xarelto. Janssen Phar-maceuticals. 2011.

[34] Rivaroxaban-drug-information. Available at: https://www. uptodate.com/contents/rivaroxaban-drug-information (Accessed: 13 September 2020).

[35] Xarelto (rivaroxaban) package insert. Janssen Pharmaceuticals. 2020.

[36] Astra Zeneca. Product information: Brilinta. Cambridge, UK, As-traZeneca. 2011.

[37] Ticagrelor-drug-information. Available at: https://www. uptodate.com/contents/ticagrelor-drug-information (Accessed: 13 September 2020).

[38] Barnes KM, Dickstein B, Cutler, GB, Fojo T, Bates SE. Steroid trans-port, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry. 1996; 35: 4820-4827.

[39] Brilinta (ticagrelor) package insert. Wilmington, DE: AstraZeneca LP. 2020.

[40] Tolvaptan-drug-information. Available at: https://www. uptodate.com/contents/tolvaptan-drug-information (Accessed: 13 September 2020).

[41] Samsca (tolvaptan) package insert. Tokyo, Japan: Otsuka Pharmaceu-ticals Co., Ltd. 2017.

[42] Warfarin-drug-information. Available at: https://www. uptodate.com/contents/warfarin-drug-information (Accessed: 2 September 2020).

[43] Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Annals of Internal Medicine. 1994; 121: 676-683.

[44] Androderm (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc. 2020.

[45] Dapagliflozin-drug-information. Available at: https: //www.uptodate.com/contents/dapagliflozin-drug-information (Accessed: 29 September 2020).

[46] Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity, and partial androgen deficiency. Aging Male. 2003; 6: 1-7.

[47] Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replace-ment therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology. 2006; 154: 899-906.

[48] Hobbs CJ. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. Journal of Clinical Endocrinology & Metabolism. 1996; 81: 1582-1585.

[49] Corrales JJ, Burgo RM, Garcı́a-Berrocal B, Almeida M, Alberca I, González-Buitrago JM, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism. 2004; 53: 666-672.

[50] Lee C, Kuo S, Hung Y, Hsieh C, He C, Yang T, et al. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocrine Research. 2005; 31: 139-148.

[51] Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. The Journal of Clinical Endocrinology & Metabolism. 1987; 64: 960-963.

[52] Astra Zeneca Pharmaceuticals LP. Farxiga product labeling. 2019. Availabie at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69 (Accessed: 29 September 2020).

[53] FDA Pharmacology Review. 2014. Available at: https: //www.accessdata.fda.gov/drugsatfda_docs/nda/2014/ 202293Orig1s000TOC.cfm (Accessed: 30 September 2020).

[54] Empagliflozin-drug-information. Available at: https: //www.uptodate.com/contents/empagliflozin-drug-information (Accessed: 30 September 2020).

[55] Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance labeling. 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&type=display (Accessed: 30 September 2020).

[56] Jardiance pharmacology review. 2011. Available at: http: //www.accessdata.fda.gov/drugsatfda_docs/nda/2011/ 201280Orig1s000PharmR.pdf (Accessed: 30 September 2020).

[57] Ertugliflozin-drug-information. Available at: https: //www.uptodate.com/contents/ertugliflozin-drug-information (Accessed: 30 September 2020).

Abstracted / indexed in

Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.

Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.

CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.

Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.

Submission Turnaround Time

Conferences

    Top